By Jason Chau
Three Chinese companies in advanced manufacturing sectors have started taking orders for their initial public offerings in Hong Kong, extending a flurry of listings from Chinese developers of cutting-edge technology, bolstered by strong policy support from Beijing.
Robotics components maker Zhejiang Laifual Drive is set to raise the most out of the three companies, seeking up to 1.15 billion Hong Kong dollars, equivalent to $146.7 million, by selling 13.4 million shares to be priced between HK$77.00 and HK$85.50 each.
Laifual Drive said proceeds will be used to expand production capacity, improve research and development capabilities, and support the growth of its overseas sales network.
The company manufactures harmonic reducers, joint modules and robotic arms used in humanoid and industrial robots for tasks such as welding and assembly. According to its filing, it was China's second-largest harmonic reducer supplier by shipment volume last year.
The company is looking to broaden its focus beyond harmonic reducers into precision transmission solutions.
Meanwhile, two other biotechnology companies are also aiming to raise funds in the red-hot Hong Kong market.
Guangdong True Health Medical Technology Development is seeking to raise up to HK$482.7 million from its IPO to be priced between HK$119.30 and HK$135.40 a share, while Jiangxi Institute of Biological Products plans to raise as much as HK$473.2 million at a range between HK$9.33 to HK$13.06 each.
True Health said it plans to use the funds raised to support research and development, product commercialization and the expansion of its manufacturing capacity.
Founded in 2018, True Health develops percutaneous puncture and ablation surgical robots used to treat lung and abdominal puncture, as well as liver and lung tumors.
Jiangxi Institute said proceeds will be directed toward research and development, facility construction and upgrading its technologies.
Jiangxi is the world's largest provider and exporter of human tetanus antitoxins, according to its filing. The company saw significant revenue growth in recent years from a booming human antiserum market, though it is projecting net profit to fall substantially this year.
The three offerings continue a strong streak of listing activity in the Asian financial hub as investor optimism toward China's tech sector remains strong. According to Hong Kong's exchange, companies listing in the city raised around HK$166.8 billion in the first five months of 2026, more than double the amount raised during the same period a year earlier.
All three offerings are scheduled to close on June 25, with shares expected to start trading on June 30.
Write to Jason Chau at jason.chau@wsj.com
(END) Dow Jones Newswires
June 21, 2026 23:20 ET (03:20 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.
Comments